FMP

FMP

Enter

5CV.F - CureVac N.V.

Profile of CureVac N.V.(5CV.F), CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformati

About

ceo

Dr. Alexander Zehnder M.B.A., M.D.

sector

Healthcare

industry

Biotechnology

website

https://www.curevac.com

exchange

XETRA

Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

CIK

N/A

ISIN

NL0015436031

CUSIP

N/A

Address

Friedrich-Miescher-Strasse 15

Phone

49 7071 9883 0

Country

DE

Employee

904

IPO Date

Aug 14, 2020

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep